New mRNA combo for lung cancer trial pulled before it began
NCT ID NCT07073183
First seen Jun 05, 2026 · Last updated Jun 18, 2026 · Updated 3 times
Summary
This study aimed to test a new mRNA treatment (CVHNLC) plus the immunotherapy drug pembrolizumab in people with advanced squamous non-small-cell lung cancer. The goal was to find a safe dose and see if adding chemotherapy later could help. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HM - Hôpital Nord
Marseille, France
-
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
-
Gustave Roussy
Villejuif, France
-
Hospital Quironsalud Barcelona -NEXT Oncology
Barcelona, Spain, Spain
-
Hospital Regional Universitario Virgen de la Victoria
Málaga, Spain, Spain
-
Hospital Universitari Vall d´Hebron -Instituto de Investigacion Oncologica Vall dHebron (VHIO)
Barcelona, Spain, Spain
-
Hospital Universitario Fundacion Jimenez Diaz - START MADRID
Madrid, Spain, Spain
-
Hospital Universitario HM Sanchinarro - CIOCC - START MADRID
Madrid, Spain, Spain
-
Institut Claudius Regaud - PPDS
Toulouse, France
-
Institut Curie - Hôpital de Paris
Paris, France
-
Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS
Saint-Herblain, France
-
Virginia Cancer Center
Fairfax, Virginia, 22031, United States
-
Virginia Commonwealth University, Massey Comprehensive Cancer Center, McGlothlin Medical Education Center
Richmond, Virginia, 23298, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.